1. Home
  2. LEGN vs HIMS Comparison

LEGN vs HIMS Comparison

Compare LEGN & HIMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • HIMS
  • Stock Information
  • Founded
  • LEGN 2014
  • HIMS 2017
  • Country
  • LEGN United States
  • HIMS United States
  • Employees
  • LEGN N/A
  • HIMS N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • HIMS Medical/Nursing Services
  • Sector
  • LEGN Health Care
  • HIMS Health Care
  • Exchange
  • LEGN Nasdaq
  • HIMS Nasdaq
  • Market Cap
  • LEGN 7.0B
  • HIMS 6.0B
  • IPO Year
  • LEGN 2020
  • HIMS N/A
  • Fundamental
  • Price
  • LEGN $31.78
  • HIMS $51.98
  • Analyst Decision
  • LEGN Strong Buy
  • HIMS Hold
  • Analyst Count
  • LEGN 13
  • HIMS 12
  • Target Price
  • LEGN $79.42
  • HIMS $37.67
  • AVG Volume (30 Days)
  • LEGN 1.5M
  • HIMS 46.8M
  • Earning Date
  • LEGN 05-13-2025
  • HIMS 05-05-2025
  • Dividend Yield
  • LEGN N/A
  • HIMS N/A
  • EPS Growth
  • LEGN N/A
  • HIMS N/A
  • EPS
  • LEGN N/A
  • HIMS 0.68
  • Revenue
  • LEGN $627,241,000.00
  • HIMS $1,784,353,000.00
  • Revenue This Year
  • LEGN $65.96
  • HIMS $60.78
  • Revenue Next Year
  • LEGN $52.55
  • HIMS $18.96
  • P/E Ratio
  • LEGN N/A
  • HIMS $76.25
  • Revenue Growth
  • LEGN 119.97
  • HIMS 85.99
  • 52 Week Low
  • LEGN $29.27
  • HIMS $12.07
  • 52 Week High
  • LEGN $60.87
  • HIMS $72.98
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 41.49
  • HIMS 75.47
  • Support Level
  • LEGN $30.25
  • HIMS $38.21
  • Resistance Level
  • LEGN $35.81
  • HIMS $54.75
  • Average True Range (ATR)
  • LEGN 1.45
  • HIMS 3.97
  • MACD
  • LEGN -0.18
  • HIMS 2.77
  • Stochastic Oscillator
  • LEGN 27.58
  • HIMS 90.65

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About HIMS Hims & Hers Health Inc.

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.

Share on Social Networks: